Basic Information


GTO ID GTC1459
Trial ID NCT01953900
Disease Neuroblastoma | Osteosarcoma
Altered gene GD2
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment GD2 CAR-T cells
Co-treatment VZV vaccine
Generation3rd
PhasePhase1
Recruitment statusActive, Not Recruiting
TitleIC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
Year2014
CountryUnited States
Company sponsorBaylor College of Medicine
Other ID(s)H-32335 VEGAS|VEGAS|P01CA094237
Vector information
Vectorretrovirus
ConstructscFv-CD28-OX40-CD3ζ
Transgene/Inserted gene14g2a ScFv; short spacer from the CH2 domain of IgG1; CD28 transmembrane and intracellular signaling domains from CD28, OX40 and CD3 ζ
Additional featureiC9, VZV specific

Clinical Result

Cohort1: dose level 1_GD2 T cells followed by VZV vaccine
Administration route intravenous infusion
Dosage 1E6 cells/m^2, 1E7 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion No
References PMID: 28183713
Cohort2: dose level 2_VZV vaccine followed by GD2 T cells
Administration route intravenous infusion
Dosage 1E7 cells/m^2, 1E8 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion No
References PMID: 28183713
Cohort3: dose level 3_Lymph depletion
Administration route intravenous infusion
Dosage 1E8 cells/m^2, 5E8 cells/m^2, 1E9 cells/m^2
Donor type Autologous
Age Child, Adult, Older_Adult
Lymph depletion Yes
References PMID: 28183713

Relationship Graph

Overview of Knowledge Graph